The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin
Abstract
Cancer cells that develop resistance to chemotherapeutic agents are a major clinical obstacle in the successful treatment of breast cancer. Acquired cancer chemoresistance is a multifactorial phenomenon, involving various mechanisms and processes. Recent studies suggest that chemoresistance may be linked to drug‐induced dysregulation of microRNA function. Furthermore, mounting evidence indicates the existence of similarities between drug‐resistant and metastatic cancer cells in terms of resistance to apoptosis and enhanced invasiveness. We studied the role of miRNA alterations in the acquisition of cisplatin‐resistant phenotype in MCF‐7 human breast adenocarcinoma cells. We identified a total of 103 miRNAs that were overexpressed or underexpressed (46 upregulated and 57 downregulated) in MCF‐7 cells resistant to cisplatin. These differentially expressed miRNAs are involved in the control of cell signaling, cell survival, DNA methylation and invasiveness. The most significantly dysregulated miRNAs were miR‐146a, miR‐10a, miR‐221/222, miR‐345, miR‐200b and miR‐200c. Furthermore, we demonstrated that miR‐345 and miR‐7 target the human multidrug resistance‐associated protein 1. These results suggest that dysregulated miRNA expression may underlie the abnormal functioning of critical cellular processes associated with the cisplatin‐resistant phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., Coppola, D., & Cheng, J. Q. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806041200 · Cited by 509
RetractedAcharya, C. R., Hsu, D. S., Anders, C. K., Anguiano, A., Salter, K. H., Walters, K. S., Redman, R. C., Tuchman, S. A., Moylan, C. A., Mukherjee, S., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1574 · Cited by 108
RetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
miRBase: tools for microRNA genomics
Griffiths-Jones, S., Saini, H. K., van Dongen, S., & Enright, A. J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm952 · Cited by 4,382
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Cited by
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer
Svoronos, A. A., Engelman, D. M., & Slack, F. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0359 · Cited by 791
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Humphries, B., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3052 · Cited by 346
MiR-200, a new star miRNA in human cancer
Feng, X., Wang, Z., Fillmore, R., & Xi, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.11.004 · Cited by 342
miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy
Garofalo, M., Quintavalle, C., Romano, G., M. Croce, C., & Condorelli, G. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376170 · Cited by 331
TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer
Stinson, S., Lackner, M. R., Adai, A. T., Yu, N., Kim, H.-J., O’Brien, C., Spoerke, J., Jhunjhunwala, S., Boyd, Z., Januario, T., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001538 · Cited by 303
Garcia, A. I., Buisson, M., Bertrand, P., Rimokh, R., Rouleau, E., Lopez, B. S., Lidereau, R., Mikaélian, I., & Mazoyer, S. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100136 · Cited by 265
GAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
The role of miRNA in the direct and indirect effects of ionizing radiation
Dickey, J. S., Zemp, F. J., Martin, O. A., & Kovalchuk, O. (2011) · Radiation and Environmental Biophysics · doi:10.1007/s00411-011-0386-5 · Cited by 88
Self-citationA microRNA Signature Associated with Early Recurrence in Breast Cancer
Pérez-Rivas, L. G., Jerez, J. M., Carmona, R., de Luque, V., Vicioso, L., Claros, M. G., Viguera, E., Pajares, B., Sánchez, A., Ribelles, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091884 · Cited by 67
Metadata
- Authors
- Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-08-20
- Volume
- 127
- Issue
- 8
- Pages
- 1785-1794
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2003631713
- Cited by
- 334
- References
- 42
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.